Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public health funding are ...
CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration, projecting strong growth and margin expansion in 2025. Next: Access Our New, Shockingly Simple 'Alert System' Novartis AG NVS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback